Scientific publications

Publications by CytomX scientists and articles related to protease biology and the Probody platform.

The following contains links to websites owned and operated by third parties. If you use these links you leave our website. These links are provided for your information and convenience only and are not an endorsement by CytomX Therapeutics, Inc. of the content of such linked websites. CytomX has no control of the content of any linked website and is not responsible for these websites or their content or availability. CytomX therefore makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by or the information contained on them.

Preliminary Interim Results of the First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial of the PD-L1 Probody Therapeutic (Pb-Tx) CX-072 in Combination with Ipilimumab (ipi) in Patients (pts) with Advanced Solid Tumors

Rachel E. Sanborn, Catharina Wilhelmina Menke, Karen A. Autio, Hendrik-Tobias Arkenau, Javier Garcia Corbacho, Patricia LoRusso, Elizabeth Ruth Plummer, Nataliya Volodymyrivna Uboha, Morganna Louise Freeman, Jerzy Wydmanski, Vanessa Huels, Beiyao Zheng, Matthias Will, Rachel W. Humphrey, Fiona Thistlethwaite, Elisabeth G.E. de Vries, Anthony B. El-Khoueiry; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR; VUMC Cancer Centre Amsterdam, Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center, New York, NY; Sarah Cannon Research Institute UK Limited, London, United Kingdom; Hospital Clínic Barcelona, Barcelona, Spain; Yale University School of Medicine–Yale Cancer Center, New Haven, CT; Northern Centre for Cancer Care, Newcastle-upon-Tyne, United Kingdom; University of Wisconsin Carbone Cancer Center, Madison, WI; The Angeles Clinic and Research Institute, Los Angeles, CA; NZOZ Vegamed, Katowice, Poland; CytomX Therapeutics, South San Francisco, CA; The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom; Universitair Medisch Centrum Groningen, Groningen, Netherlands; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

Download

Preliminary Results of the First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial of the PD-L1 Probody Therapeutic CX-072 as Monotherapy in Patients (pts) with Advanced Solid Tumors

Karen A. Autio, Hendrik-Tobias Arkenau, Bert H. O’Neil, Johanna C. Bendell, Anthony El-Khoueiry, James Strauss, Amy Weise, Nataliya Volodymyrivna Uboha, Naiyer A. Rizvi, Beiyao Zheng, Luc Desnoyers, Mark Stroh, Lori Carman, Rachel W. Humphrey, Matthias Will, Valentina Boni, Alexander I. Spira, Aung Naing; Memorial Sloan Kettering Cancer Center, New York, NY; Sarah Cannon Research Institute UK Limited, London, United Kingdom; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Mary Crowley Medical Research Center, Dallas, TX; Barbara Ann Karmanos Cancer Institute, Detroit, MI; University of Wisconsin Carbone Cancer Center, Madison, WI; Columbia University Medical Center, New York, NY; CytomX Therapeutics, South San Francisco, CA; START Madrid CIOCC, Hospital HM Universitario Sanchinarro, Madrid, Spain; Virginia Cancer Specialists, Fairfax, VA; University of Texas, MD Anderson Cancer Center, Houston, TX

Download

Development of a ProbodyTM Drug Conjugate (PDC) Targeting CD166 for the Treatment of Multiple Cancers – AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Annie Yang Weaver, Shweta Singh, Amy DuPage, Jason Sagert, Jeanne Flandez, Elizabeth Menendez, Judi Ford, Michael Krimm, Stephen Moore, Margaret Nguyen, Andrew Jang, Eric Brecht, Yuanhui Huang, Linnea Diep, Nicole Lapuyade, Tereza Sputova, James West, Olga Vasiljeva, Shouchun Liu, Jennifer Richardson, W. Michael Kavanaugh, Jonathan A. Terrett, Luc R. Desnoyers

Download

A PD-L1-targeted Probody™ Therapeutic Provides Anti-Tumor Efficacy While Minimizing Induction of Systemic Autoimmunity in Preclinical Studies – CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference

Chihunt Wong, Li Mei, Kenneth R. Wong, Jennifer Razo, Chanty Chan, Elizabeth Menendez, Shouchun Liu, Olga Vasiljeva, Jennifer H. Richardson, James W. West, W. Michael Kavanaugh, Bryan A. Irving

Download

PD-1 Probody™ Therapeutic Anti-tumor Efficacy and Protection Against Autoimmunity in Preclinical Models – AACR 2016

Kimberly A. Tipton, Chanty Chan, Kenneth R. Wong, Victoria Singson, Laura P. Serwer, Yuanhui Huang, Shouchun Liu, Jennifer H. Richardson, W. Michael Kavanaugh, Bryan A. Irving and James W. West.

Download

Preclinical Development of a Probody™ Drug Conjugate (PDC) Targeting CD71 for the Treatment of Multiple Cancers – AACR 2016

Shweta Singh, Amy DuPage, Annie Yang Weaver, Michael Krimm, Clayton White, Jason Sagert ,Yuanhui Huang, Linnea Diep, Shouchun Liu, Jennifer Richardson, W. Michael Kavanaugh, Jonathan A. Terrett, Luc R. Desnoyers.

Download

Probody™ Therapeutic Targeting PD-1 Provides Preclinical Anti-tumor Efficacy While Minimizing Induction of Autoimmunity as a Single Agent and in Combination with CTLA-4 Blockade

Kimberly A. Tipton, Kenneth R. Wong, Victoria Singson, Chihunt Wong, Chanty Chan, Yuanhui Huang, Shouchun Liu, Jennifer H. Richardson, W. Michael Kavanaugh, James W. West and Bryan A. Irving, SITC, November 2016

Download

PROCLAIM-CX-072: A First-in-Human Trial to Assess Tolerability of the Protease-Activatable Anti–PD-L1 Probody™ CX-072 in Solid Tumors and Lymphomas

Alexander I. Spira, M.D., Ph.D., F.A.C.P., Medical Oncologist and Director, Virginia Cancer Specialists Research Institute and Oncology Research, et. al., ASCO, June 2017

Download

PROCLAIM-CX-2009: A First-in-Human Trial to Evaluate CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors – ESMO 2017

Javier Garcia-Corbacho, Alexander Spira, Valentina Boni, Jaime Feliu, Mark Middleton, Howard Burris, Annie Yang Weaver, Matthias Will, James Harding, Funda Meric-Bernstam, Volker Heinemann

Download

EGFR-CD3 Bispecific Probody™ Therapeutic Induces Tumor Regressions and Increases Maximum Tolerated Dose > 60 fold in Preclinical Studies – AACR-NCI-EORTC 2017

Leila M. Boustany, Sherry L. La Porte*, Laurie Wong, Clayton W. White, Linnea Diep, Yuanhui Huang, Shouchun Liu, Jennifer H. Richardson, W. Michael Kavanaugh, Bryan A. Irving

Download

Developing a CD71-Targeting Probody™ Drug Conjugate (PDC) for Activity in Multiple Solid Tumor and Lymphoma Models and for Tolerability in Non-human Primates

Shweta Singh1, Laura Serwer1, Niharika Chauhan2, Amy DuPage1, Michael Krimm1, Ken Wong1, Yuanhui Huang1, Andrew Jang1, Eric Ureno1, Adam Miller1, Sarah Patrick1, Shanti Duvur1, Fritz Buchanan2, Matthew Ravn2, Rob Leanna2, Ilaria Badagnani3, Tracy Henriques2, Shouchun Liu1, Luc Desnoyers1, Claus Krebber1, Sridhar Viswanathan1, Jennifer Richardson1, Susan Morgan-Lappe2 and W. Michael Kavanaugh1

1CytomX Therapeutics, Inc., South San Francisco, CA; 2AbbVie, North Chicago, IL, 3Former Abbvie Employee

Download

A Multi-Analyte HPLC-MS/MS Approach to Assessing Exposure of a Probody™ Drug Conjugate in Preclinical Studies

Laura P. Serwer1, Shweta Singh1, Claus Krebber1, Shouchun Liu1, Niharika Chauhan2, Robert Leanna2, Hong Lu1, Ilaria Badagnani4, Tracy Henriques2, Susan Morgan-Lappe2, William Mylott Jr. 3, Sridhar Viswanathan1, Jennifer H. Richardson1, W. Michael Kavanaugh1

1CytomX Therapeutics, Inc., South San Francisco, CA; 2AbbVie, North Chicago, IL; 3PPD Laboratories, Richmond, VA, 4Former AbbVie Employee

Download

In vivo imaging of protease activity by Probody therapeutic activation

Biochimie; Vasiljeva, O. et al; November 2015

Read More

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

Science Translational Medicine; Desnoyers, L., Vasiljeva, O., Richardson, J., Yang, A., Menendez, E., Liang, T.,… Lowman, H.; October 2013

Read More

Imaging a functional tumorigenic biomarker in the transformed epithelium

Proceedings of the National Academy of Sciences USA; LeBeau, A. et al; January 2013

Read More

Identification of protease exosite-interacting peptides that enhance substrate cleavage kinetics

Biological Chemistry; Jabaiah, A. et al; September 2012

Read More

Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases

Journal of Controlled Release; Erster, O. et al; August 2012

Read More

Emerging principles in protease-based drug discovery

Nature Reviews Drug Discovery; Drag, M. et al; September 2010

Read More

Evolutionary optimization of peptide substrates for proteases that exhibit rapid hydrolysis kinetics

Biotechnology and Bioengineering; Boulware, K. et al; June 2010

Read More

Tumor detection by imaging proteolytic activity

Cancer Research; Darragh, M. et al; February 2010

Read More

Methods for the proteomic identification of protease substrates

Current Opinion in Chemical Biology; Agard, N. et al; December 2009

Read More

The urokinase plasminogen activator system: a target for anti-cancer therapy

Current Cancer Drug Targets; Ulisse, S. et al; February 2009

Read More

Matrix metalloproteases: underutilized targets for drug discovery

Journal of Drug Targeting; Vartak, D. et al; January 2007

Read More

Matriptase and its putative role in cancer

Cellular and Molecular Life Sciences; Uhland, K. et al; December 2006

Read More

Protease specificity determination by using cellular libraries of peptide substrates (CLiPS)

Proceedings of the National Academy of Sciences USA; Boulware, K. et al; May 2006

Read More

Bacterial display using circularly permuted outer membrane protein OmpX yields high affinity peptide ligands

Protein Science; Rice, J. et al; April 2006

Read More

Proteases, extracellular matrix, and cancer: a workshop of the path B study section

American Journal of Pathology; DeClerck, Y. et al; April 2004

Read More